Renovorx reports second quarter 2022 financial results

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary renovorx trans-arterial micro-perfusion (renovotamptm) therapy platform, today reported its financial results for the quarter ended june 30, 2022. “over the past decade, our team has developed and refined a unique therapy platform for difficult-to-treat solid tumors by localizing and targeting chemotherapy to
RNXT Ratings Summary
RNXT Quant Ranking